Thermo Fisher Scientific to Acquire Clario, Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for $8.875 billion in cash at close plus potential additional earnout and other payments in the future, largely dependent on performance.
Read the full press release on the Thermo Fisher Scientific website